About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Schizophrenia Clinical Trials in Chicago | 196 Studies

Clinical Trials SchizophreniaChicago

Schizophrenia Clinical Trials in Chicago

Find 196 clinical trials for schizophrenia near Chicago, Illinois. Connect with research centers in your area.

All Schizophrenia trials nationwide All trials in Chicago

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 41-60 of 196 trials

CompletedLong-term Study of Cariprazine in Patients With SchizophreniaThe objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.NCT01104792·Little Rock, Arkansas and 85 others

Schizophrenia Trials in Other Cities

New York Los Angeles Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TerminatedEfficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant SchizophreniaThis study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant…NCT03230864·San Diego, California and 40 others

CompletedRelative Bioavailability of LY03010 Compared to Listed DrugThis is a randomized, multiple-dose, open-label, parallel-group study.NCT04922593·Garden Grove, California and 8 others

CompletedA Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With SchizophreniaThe study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute…NCT01469039·Little Rock, Arkansas and 83 others

CompletedA Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsThis phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with…NCT03818256·Bentonville, Arkansas and 26 others

CompletedA Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective DisorderThis study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective…NCT04512066·Little Rock, Arkansas and 39 others

CompletedStudy of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyThe purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable…NCT01716975·Phoenixville, Arizona and 105 others

CompletedA Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of SchizophreniaThis study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.NCT03345979·Little Rock, Arkansas and 15 others

CompletedEfficacy Study of Early Onset of Antipsychotic Drug Action in SchizophreniaThe current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.NCT00337662·Little Rock, Arkansas and 33 others

CompletedA Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaThis is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current…NCT05145413·Phoenix, Arizona and 165 others

CompletedTrial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With SchizophreniaThe purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total) of CVL-231 on ambulatory blood pressure and heart rate in patients with stable…NCT05245539·Bentonville, Arkansas and 9 others

CompletedAn Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)This is an extension of a previous study (ALK9072-003EXT).NCT01895452·Little Rock, Arkansas and 56 others

CompletedA Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderThis double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).NCT02161718·Little Rock, Arkansas and 70 others

CompletedHigh Dose Lurasidone for Patients With Treatment Resistant SchizophreniaThe aim of this study is to compare the efficacy of a flexible high dose of lurasidone to a standard dose of lurasidone in patients with treatment resistant schizophrenia or…NCT01569659·Chicago, Illinois and 1 other

CompletedA Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaThis is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.NCT01655680·Anaheim, California and 60 others

CompletedStudy of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of SchizophreniaThis study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms…NCT05838625·Chandler, Arizona and 53 others

RecruitingNBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaThis study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.NCT07114874·Bryant, Arkansas and 60 others

CompletedEfficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophreniaNCT02970292·Phoenix, Arizona and 104 others

CompletedIntramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaTo evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.NCT00731549·Chandler, Arizona and 213 others

CompletedA Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaThis is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of…NCT05227703·Bentonville, Arkansas and 25 others

PreviousPage 3 of 10Next

Other Conditions in Chicago

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia